Q1 2026 Sangamo Therapeutics Inc Earnings Call Transcript

May 14, 2026 / 08:30 PM GMT

Release Date Price: $0.144 (-0.69%)

Transcript 10-Q8-K

Key Points

Positve

Sangamo Therapeutics Inc (SGMO) has made progress in the rolling submission of the BLA for ST920 in Fabry disease, with the first two modules submitted.
The FDA has reaffirmed that an additional confirmatory study will not be required for ST920, which could expedite the approval process.
Sangamo's neurology pipeline is advancing, with six clinical sites activated for the Phase I/II study of ST503 for intractable pain.
The company presented three abstracts at the American Society of Gene and Cell Therapy Annual Meeting, showcasing advances in zinc-finger epigenetic regulation and integrase technology.
Sangamo is actively pursuing strategic opportunities to raise additional capital and maximize the value of its assets, supported by a global investment bank.

Negative

Sangamo Therapeutics Inc (SGMO) received a delisting determination from Nasdaq due to non-compliance with minimum bid requirements, leading to a transition to the OTCQB venture market.
The company is facing financial challenges and is actively seeking additional funding to continue its operations and complete the BLA submission.
There is uncertainty regarding the timing of the disclosure of the 104-week data for ST920, which could impact investor confidence.
The transition to the OTCQB market may limit Sangamo's access to capital and investor interest compared to being listed on Nasdaq.
Sangamo's business development discussions for a potential Fabry commercialization agreement are ongoing, with no definitive updates provided during the call.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SGMO.PK - Sangamo Therapeutics Inc
Q1 2026 Sangamo Therapeutics Inc Earnings Call
May 14, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, and welcome to Zagnimo's Therapeutics first-quarter 2026 teleconference call.

Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker today, Louise Wilke, Head of Investor Relations and Corporate Communications. Ma'am, please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Good afternoon, everyone.

Thank you for joining us on the call today.

On this call are several members of the Sangamo Executive Leadership team, including Sandy McRae, Chief

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.